US2006141005A1PendingUtilityA1
Compositions and medical devices utilizing bioabsorbable polymeric waxes
Est. expiryJun 29, 2021(expired)· nominal 20-yr term from priority
A61L 17/005A61L 17/145A61K 9/7007A61L 27/58A61L 27/46A61K 9/1647A61L 31/06A61L 2300/602A61K 9/204A61L 31/148A61L 27/18Y10T428/1352
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to medical devices, pharmaceutical or agricultural compositions, and seeds, each containing a synthetic, bioabsorbable, biocompatible polymeric wax that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the polymeric wax having a melting point less than about 70° C., as determined by differential scanning calorimetry.
Claims
exact text as granted — not AI-modified1 . A medical device, comprising:
a) a synthetic, bioabsorbable, biocompatible polymeric wax comprising the reaction product of a polybasic acid or derivative thereof, and a monoglyceride, said monoglyceride selected from the group consisting of monostearoyl glycerol, monopalmitoyl glycerol, monomyrisitoyl glycerol, monocaproyl glycerol, monodecanoyl glycerol, monolauroyl glycerol, monolinoleoyl glycerol and monooleoyl glycerol, said polymeric wax having a melting point less than about 70° C., as determined by differential scanning calorimetry, and b) an effective amount of a bioactive agent.
2 . (canceled)
3 . The medical device of claim 1 wherein said polybasic acid or derivative thereof is selected from the group consisting of succinic acid, succinic anhydride, malic acid, tartaric acid, citric acid, diglycolic acid, diglycolic anhydride, glutaric acid, glutaric anhydride, adipic acid, pimelic acid, suberic acid, sebacic acid, fumaric acid, maleic acid, maleic anhydride, mixed anhydrides, esters, activated esters and acid halides.
4 . (canceled)
5 . The medical device of claim 3 wherein said polybasic acid derivative is succinic anhydride.
6 . The medical device of claim 3 wherein said polybasic acid is succinic acid.
7 . The medical device of claim 1 wherein said polymeric wax has a number average molecular weight between about 1,000 g/mole and about 100,000 g/mole, as measured by gel permeation chromatography using polystyrene standards.
8 . The medical device of claim 1 wherein said polymeric wax is branched.
9 . The medical device of claim 1 wherein said polymeric wax comprises a copolymer.
10 . The medical device of claim 9 wherein said polymeric wax copolymer comprises the reaction product of at least two of said polybasic acids or derivatives thereof selected from the group consisting of succinic acid, succinic anhydride, malic acid, tartaric acid, citric acid, diglycolic acid and diglycolic anhydride.
11 . The medical device of claim 9 wherein said polymeric wax copolymer comprises the reaction product of said polybasic acid or derivative thereof, and at least two monoglycerides selected from the group consisting of monostearoyl glycerol, monopalmitoyl glycerol, monomyrisitoyl glycerol, monocaproyl glycerol, monodecanoyl glycerol, monolauroyl glycerol, monolinoleoyl glycerol and monooleoyl glycerol.
12 . The medical device of claim 9 wherein said wax copolymer comprises the reaction product of said polybasic acid or derivative thereof, a monoglyceride selected from the group consisting of monostearoyl glycerol, monopalmitoyl glycerol, monomyrisitoyl glycerol, monocaproyl glycerol, monodecanoyl glycerol, monolauroyl glycerol, monolinoleoyl glycerol and monooleoyl glycerol, and at least one polyol selected from the group consisting of ethylene glycol, 1,2-propylene glycol, 1,3-propanediol, bis-2-hydroxyethyl ether, 1,4-butanediol, 1,5-pentanediol, 1,6- hexanediol, 1,8-octanediol, 1,10-decanediol, 1,12-dodecanediol, other diols, linear poly(ethylene glycol) branched poly(ethylene glycol), linear poly(propylene glycol), branched poly(propylene glycol), linear poly(ethylene-co-propylene glycol)s and branched poly(ethylene-co-propylene glycol)s.
13 . (canceled)
14 . The medical device of claim 1 further comprising an aliphatic polyester prepared from monomers selected from the group consisting of glycolide, L-lactide, D-lactide, meso-lactide, rac-lactide, ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,4-dioxanone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and substituted derivatives thereof.
15 . The medical device of claim 1 comprising a coating of said polymeric wax.
16 . The medical device of claim 15 further comprising an aliphatic polyester prepared from the group of monomers consisting of glycolide, L-lactide, D-lactide, meso-lactide, rac-lactide, ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,4-dioxanone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and substituted derivatives thereof.
17 . The medical device of claim 1 comprising a bone replacement material comprising said polymeric wax and an inorganic filler.
18 . The medical device of claim 17 wherein said polymeric wax is the reaction product of succinic anhydride and a monoglyceride selected from the group consisting of monostearoyl glycerol, monopalmitoyl glycerol, monomyrisitoyl glycerol, monocaproyl glycerol, monodecanoyl glycerol, monolauroyl glycerol, monolinoleoyl glycerol and monooleoyl glycerol.
19 . The medical device of claim 17 wherein said inorganic filler is selected from the group consisting of alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium carbonate, barium carbonate, calcium sulfate, barium sulfate and hydroxyapatite.
20 . The medical device of claim 17 wherein said inorganic filler comprises a polymorph of calcium phosphate.
21 . The medical device of claim 17 wherein said inorganic filler is hydroxyapatite.
22 . (canceled)
23 . The medical device of claim 21 wherein said bioactive agent is a growth factor.
24 . The medical device of claim 17 wherein said bone replacement material comprises a biologically derived substance selected from the group consisting of demineralized bone, platelet rich plasma, bone marrow aspirate and bone fragments.
25 . The medical device of claim 24 wherein said polymeric wax is the reaction product of succinic anhydride and a monoglyceride selected from the group consisting of monostearoyl glycerol, monopalmitoyl glycerol, monomyrisitoyl glycerol, monocaproyl glycerol, monodecanoyl glycerol, monolauroyl glycerol, monolinoleoyl glycerol and monooleoyl glycerol.
26 . The medical device of claim 24 wherein said inorganic filler is selected from the group consisting of alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium carbonate, barium carbonate, calcium sulfate, barium sulfate and hydroxyapatite.
27 . The medical device of claim 24 wherein said bone replacement material further comprises the effective amount of the bioactive agent.
28 . The medical device of claim 27 wherein the bioactive agent is a growth factor.
29 . The medical device of claim 17 further comprising an aliphatic polyester prepared from the group of monomers consisting of glycolide, glycolide, L-lactide, D-lactide, meso-lactide, rac-lactide, ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,4-dioxanone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and substituted derivatives thereof.
30 . The medical device of claim 22 further comprising an aliphatic polyester prepared from the group of monomers consisting of glycolide, L-lactide, D-lactide, meso-lactide, rac-lactide, ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,4-dioxanone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one and substituted derivatives thereof.
31 . The medical device of claim 1 selected from the group consisting of sutures, stents, vascular grafts, stent-graft combinations, meshes, tissue engineering scaffolds, pins, clips, staples, films, sheets, foams, anchors, screws and plates.
32 - 55 . (canceled)
56 . The device of claim 1 wherein said polymeric wax has a melting point between about 25° C. and about 70° C.
57 - 58 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.